HPAPI & API Development Capabilities Updates
-
Bend Bioscience Capabilities Update May 2026: Highly Potent Drug Development & Manufacturing
5/29/2026
Discover how Bend Bioscience is scaling High Science + High Service through expanded capacity and targeted investments.
-
Recipharm Capabilities Update May 2026: Highly Potent Drug Development & Manufacturing
5/29/2026
Bringing a high potency product to market is rarely straightforward, especially when timelines slip, API is scarce and processes don't scale as planned.
-
Curia Capabilities Update May 2026: HPAPI & API Development
5/28/2026
What is critical when choosing a CDMO as a partner for HPAPI development and manufacturing? Curia's Brian Haney breaks down the key questions, controls, and expertise every innovator should evaluate.
-
Ardena Capabilities Update May 2026: HPAPI & API Development
5/28/2026
Learn how integrated, science-led CDMO/CRO strategies can manage the full complexity of high-potent drug development — from containment-focused manufacturing and ultra-sensitive analytics to product delivery.